Program
leuprolide mesylate
Also written as “Leuprolide Mesylate” and “Leuprolide Injectable Emulsion (CAMCEVI®)”.
Its studies are mostly in Prostatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Foresee Pharmaceuticals | 20 open or running | phase 3since Sep 1, 2014 | Sep 1, 2014 | none ahead |
| Changchun GeneScience Pharmaceutical | 10 open or running | phase 3since May 11, 2025 | May 11, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 1, 2014First study: phase 3 study in Prostatic NeoplasmsNew to Foresee PharmaceuticalsForesee Pharmaceuticals · NCT02234115 · 137 enrolled · United States, Austria, Czechia and more
- Aug 19, 2017Phase 3 study in Prostatic NeoplasmsForesee Pharmaceuticals · NCT03261999 · 144 enrolled · United States, Czechia, Korea, Republic of and more
- May 11, 2025Changchun GeneScience Pharmaceutical's first study: phase 3 study in Advanced Prostate CancerNew to Changchun GeneScience PharmaceuticalChangchun GeneScience Pharmaceutical · NCT06984159 · 137 enrolled · China
TargetBeta
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Other programs on GNRHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Leuproliderule | Takeda | phase 4 | 39 |
| triptorelinrule | Ipsen | phase 4 | 21 |
| Goserelinrule | AstraZeneca | phase 4 | 14 |
| linzagolixrule | Kissei Pharmaceutical | phase 3 | 14 |
| GnRH Antagonist SHR7280 | Jiangsu HengRui Medicine | phase 3 | 10 |
| Gonadotropin-Releasing Hormonerule | Ferring Pharmaceuticals | phase 3 | 5 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06984159Advanced Prostate Cancer · China | 3 | Completed | Changchun GeneScience Pharmaceutical | Nov 30, 2023 | 137 |
| NCT03261999Prostatic Neoplasms · United States, Czechia, Korea, Republic of and more | 3 | Completed | Foresee Pharmaceuticals | Nov 19, 2018 | 144 |
| NCT02234115Prostatic Neoplasms · United States, Austria, Czechia and more | 3 | Completed | Foresee Pharmaceuticals | Aug 30, 2016 | 137 |
How it is read
Names in the registry
- “Leuprolide Mesylate”, 2 entries
- “Leuprolide Injectable Emulsion (CAMCEVI®)”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.